(Q40866031)

24 September 2017

title

BRAF inhibitors - do we need to worry about kidney injury? (English)

1 reference

24 September 2017

Rimda Wanchoo

1

1 reference

24 September 2017

Craig Devoe

series ordinal

2

1 reference

24 September 2017

Kenar D Jhaveri

series ordinal

3

1 reference

24 September 2017

language of work or name

English

0 references

publication date

8 March 2016

1 reference

Expert Opinion on Drug Safety

24 September 2017

published in

1 reference

24 September 2017

volume

15

1 reference

24 September 2017

issue

5

1 reference

24 September 2017

page(s)

579-581

1 reference

Initial genome sequencing and analysis of multiple myeloma

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Vemurafenib significantly decreases glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1164139

10.1517/14740338.2016.1164139

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference